News | February 10, 2014

On-X Life Technologies Gain CE Marking for Mechanical Aortic Heart Valve

On-X Life Technologies On-X Plus 1.5 Aortic Heart Valve Repair Cardiovascular
February 10, 2014 — On-X Life Technologies Inc.  received CE marking for an expanded labeling claim of its On-X Prosthetic Heart Valve. The company may market its mechanical heart valve in Europe with areduced requirement for the use of blood-thinning drugs such as warfarin. The On-X Plus 1.5 Aortic Heart Valve allows patients to be managed at INR (international normalized ratio) levels as low as 1.5.
The expanded labeling claim was supported by interim data from a recently completed arm of an U.S. Food and Drug Administration (FDA) IDE clinical trial, “Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT).” Principal Investigator John D. Puskas, M.D., cardiothoracic surgery, Emory University, Atlanta, presented results at the annual scientific meeting of the American Association for Thoracic Surgery (AATS). These data demonstrated the safety of maintaining On-X Prosthetic Heart Valve patients on a reduced anticoagulation therapy regimen while decreasing bleeding complications by more than 50 percent.
The On-X heart valve is the result of a medical grade carbon technology: On-X pure pyrolytic carbon. In addition to providing a more thromboresistant surface, the comparatively high strength of pure On-X Carbon has enabled On-X LTI to make valve design changes that have resulted in a prosthesis that acts more like a natural valve in its treatment of blood. Clinical studies have documented that the On-X valve does not produce the turbulence and blood damage commonly produced by other mechanical heart valve prostheses and, therefore, significantly reduces the potential for life-threatening blood clots.
This therapy is not approved in the United States or other countries that have reviews independent of the European Union.  In these countries On-X Life Technologies Inc., continues to recommend standard anticoagulation therapy as presently prescribed by various professional societies for the On-X valve. On-X aortic and mitral valves are FDA approved.
For more information:

Related Content

Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
ERACS Session Highlights Need for Standardized Best Practices in Cardiac Surgery
News | Cardiovascular Surgery | May 02, 2017
The recently formed group Enhanced Recovery After Cardiac Surgery (ERACS) hosted an organizing session in Boston on...
ClearFlow Receives Frost & Sullivan New Product Innovation Award for PleuraFlow Technology
News | Cardiovascular Surgery | May 01, 2017
ClearFlow Inc. has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The...
Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery | February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery | November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
Overlay Init